RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Considerations when applying a structured benefit-risk assessment to drug delivery combination products
Gilsenan, A. W., Ritchey, M. B., Hauber, A. B., & Andrews, E. B. (2019). Considerations when applying a structured benefit-risk assessment to drug delivery combination products. Pharmacoepidemiology and Drug Safety, 28(Suppl 2), 952. https://doi.org/10.1002/pds.4864
RTI shares its evidence-based research - through peer-reviewed publications and media - to ensure that it is accessible for others to build on, in line with our mission and scientific standards.
